Skip to content
Evigrade
MinorBiguanides. Oral antihyperglycemic agents×Statin (HMG-CoA reductase inhibitor)

Updated · Methodology

Mechanism

Metformin is not metabolised and is excreted unchanged by the kidneys through glomerular filtration and tubular secretion, with a half-life of about 6.5 hours (metformin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Its exposure is changed by drugs acting on the organic cation transporters OCT1 and OCT2 (metformin SmPC, AEMPS, section 4.5). Pitavastatin enters liver cells through OATP1B1 and OATP1B3 and is metabolised mainly by glucuronidation (UGT1A3 and UGT2B7), with minimal CYP involvement. It is excreted mostly in bile, with less than 5% in urine (pitavastatin SmPC, AEMPS, section 5.2). The two drugs use different transporters and enzymes. The metformin SmPC advises more frequent glucose monitoring with drugs that have intrinsic hyperglycaemic activity, such as glucocorticoids (AEMPS, section 4.5). The pitavastatin SmPC states that there is no confirmed signal of diabetes risk with pitavastatin (AEMPS, section 4.4).

Symptoms

The documents describe no symptoms caused by this combination. Lactic acidosis is a rare but serious complication of metformin. Metformin accumulates when renal function worsens acutely, which increases this risk (metformin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Like other statins, pitavastatin can cause myalgia, myopathy and, rarely, rhabdomyolysis (pitavastatin SmPC, AEMPS, section 4.4).

Management

According to the documents, the combination is acceptable and no dose change of metformin or pitavastatin is needed. Neither document names the pair, and there is no confirmed rise in blood glucose with pitavastatin (metformin and pitavastatin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4 and 4.5). People at risk of diabetes (for example, with fasting glucose of 5.6–6.9 mmol/L, obesity, raised triglycerides or hypertension) are monitored clinically and biochemically on statins, according to national guidelines (pitavastatin SmPC, AEMPS, section 4.4). Pitavastatin is used with caution in moderate or severe renal impairment, and the 4 mg dose is not recommended in severe renal impairment (pitavastatin SmPC, AEMPS, section 4.4).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Metformin

Other interactions with Pitavastatin